Clinical Trials
14 trialsNCT07197645 2026-05-14
SOLACE
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 1 Recruiting
NCT01896505 2024-01-08
A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
Karyopharm Therapeutics Inc
Phase 1 Completed
NCT03525392 2023-12-12
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
Phase 1 Terminated
NCT02736565 2023-11-13
Pbi-shRNAâ„¢ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Gradalis, Inc.
Phase 1 Completed
NCT06008483 2023-08-23
A Dose Finding Study to Treat Bone Tumor(s)
QSAM Therapeutics, Inc.
Phase 1 Unknown
NCT01461252 2021-07-16
Safety and Efficacy of Cryoablation Combined With Radiation Therapy for the Palliation of Painful Bone Metastases
Boston Scientific Corporation
Phase 1 Withdrawn
NCT01461265 2021-07-16
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases
Boston Scientific Corporation
Phase 1 Completed
NCT04798326 2021-03-15
MW032
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT04178044 2019-11-26
Phase â… Clinical Study Protocol of GB223 Monoclonal Antibody Injection
Genor Biopharma Co., Ltd.
Phase 1 Unknown
NCT02274623 2019-09-27
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
OPKO Health, Inc.
Phase 1 Completed
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT00350233 2012-09-17
MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors
InSightec
Phase 1 Completed
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed